top of page
Search
Biologics in Autoimmune Diseases: A New Hope for Patients
Biologics in Autoimmune Diseases:
Jul 2, 20244 min read
Precision Medicine – Key Players and Pipeline
Precision medicine, with its promise of tailoring treatments to individual patient characteristics, is revolutionizing the healthcare...
Jun 27, 20247 min read
Biopharmaceutical Alliance Launched by India, South Korea, US, Japan, and EU
The global biopharmaceutical sector has taken a significant step towards ensuring a resilient drug supply chain with the formation of the...
Jun 7, 20243 min read
Import of Biological Specimens into India
A Biological specimen is a pharmaceutical product prepared by utilizing living cells and tissues to prevent, diagnose, or treat diseases....
Jun 2, 20244 min read
New Drugs, Generics and Biosimilar Registration in Singapore: Whitepaper on HSA Regulations
Guide to regulation in Singapore, insights into regulatory authorities, registration processes, & compliance for Drugs & Biosimilar
Apr 22, 20242 min read
Biologics and Biosimilar Regulations and Registration in South Korea
The Korean pharmaceutical market is estimated to be worth $24.3 billion in 2019, and between 2015 and 2019, it grew at a compound annual...
Sep 6, 20235 min read
Biologics and Biosimilars Regulation and Registration in India (CDSCO)
The size of the Indian biosimilars market, which was anticipated to be worth $349 million in 2022, is expected to increase to $2108...
Sep 1, 20237 min read
Biologics and Biosimilar Regulation and Registration in Japan (PMDA)
With the exception of the United States, Japan's biosimilar business, with a market value of $140 million, accounted for just 5% of the...
Aug 31, 20235 min read
Biologics and Biosimilar Regulations and Registration in the European Union (EU) (EMA)
In 2022, the Europe biosimilar market had a value of almost USD 4601.56 million. In addition, it is anticipated that the biosimilar...
Aug 28, 20235 min read
Biologics and Biosimilars Regulations and Registration in Mexico (COFEPRIS)
Mexico is the second-largest drug market in Latin America, after Brazil. With a compound annual growth rate (CAGR) of 38.7%, the Mexican...
Aug 23, 20235 min read
Biologics and Biosimilars Regulations and Registration in China (NMPA)
In China, 40% of the biologics market comprises biosimilars. The usage of biosimilars in oncology has increased as cancer overtook heart...
Aug 18, 20235 min read
Biologics and Biosimilar Regulations and Registration in Brazil
According to the Drugs Sector Regulation Chamber (CMED) in 2022, the Brazilian pharmaceutical sector generated US $17.2 billion in sales...
Aug 17, 20235 min read
Biologics and Biosimilars Regulations, Registration Process in the USA (FDA)
The size of the U.S. biosimilars market, estimated at USD 6.73 billion in 2021, is expected to increase by USD 9.48 billion in 2022 and...
Aug 9, 20235 min read
Insights
Global, Concurrent, Experience Based
Deep dive and engage in insightful discourse driven by concurrent global regulatory scenarios, industry trends and Artixio’s real-time experience across the product value chain. Whitepapers, research articles, landscape reports and case studies to help you stay ahead of the curve.
bottom of page